Effect of Amyloid Imaging on the Diagnosis and Management of Patients with Cognitive Decline: Impact of Appropriate Use Criteria

被引：29

作者：

Grundman, Michael ^{[1
,2
]}

Johnson, Keith A. ^{[3
]}

Lu, Ming ^{[4
]}

Siderowf, Andrew ^{[4
]}

Dell'Agnello, Grazia ^{[5
]}

Arora, Anupa K. ^{[4
]}

Skovronsky, Daniel M. ^{[4
]}

Mintun, Mark A. ^{[4
]}

Pontecorvo, Michael J. ^{[4
]}

机构：

[1] Global R&D Partners LLC, San Diego, CA USA

[2] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA

[3] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA

[4] Avid Radiopharmaceut Inc, 3711 Market St, Philadelphia, PA 19104 USA

[5] Eli Lilly & Co, Florence, Italy

来源：

DEMENTIA AND GERIATRIC COGNITIVE DISORDERS | 2016年 / 41卷 / 1-2期

关键词：

Florbetapir; Amyloid imaging; Positron emission tomography; Appropriate use criteria; Alzheimer's disease; FLORBETAPIR F 18; ALZHEIMERS-DISEASE; CLINICAL-DIAGNOSIS; NATIONAL INSTITUTE; BETA PLAQUES; TASK-FORCE; PET; DEMENTIA; MEMORY; F-18-FLUTEMETAMOL;

D O I：

10.1159/000441139

中图分类号：

R592 [老年病学]; C [社会科学总论];

学科分类号：

03 ; 0303 ; 100203 ;

摘要：

Background: Published appropriate use criteria (AUC) describe patients for whom amyloid positron emission tomography (PET) might be most useful. This study compared the impact of amyloid PET on diagnosis and management in subjects likely to either meet or not meet AUC. Methods: Physicians provided a provisional diagnosis and management plan for patients presenting with cognitive decline before and after amyloid PET imaging with florbetapir F 18. Participants were classified as AUC-like or not, based on the prescan diagnosis and demographic features. Results: In all, 125 of 229 participants (55%) were classified as AUC-like. Sixty-two percent of the AUC-like subjects had a change in diagnosis after scanning compared with 45% of the non-AUC subjects (p = 0.011). Both groups demonstrated high rates of change in their management plans after scanning (88.0% for AUC-like cases, 85.6% for non-AUC cases). Conclusions: The impact of amyloid imaging on diagnosis and planned management was maintained and, if anything, amplified in AUC-like patients. (C) 2016 S. Karger AG, Basel

引用

页码：80 / 92

页数：13

共 30 条

[1] Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010 [J].

Beach, Thomas G. ;

Monsell, Sarah E. ;

Phillips, Leslie E. ;

Kukull, Walter .

JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2012, 71 (04) :266-273

[2]

Clark CM, 2012, LANCET NEUROL, V11, P669, DOI 10.1016/S1474-4422(12)70142-4

[3] Use of Florbetapir-PET for Imaging β-Amyloid Pathology [J].

Clark, Christopher M. ;

Schneider, Julie A. ;

Bedell, Barry J. ;

Beach, Thomas G. ;

Bilker, Warren B. ;

Mintun, Mark A. ;

Pontecorvo, Michael J. ;

Hefti, Franz ;

Carpenter, Alan P. ;

Flitter, Matthew L. ;

Krautkramer, Michael J. ;

Kung, Hank F. ;

Coleman, R. Edward ;

Doraiswamy, P. Murali ;

Fleisher, Adam S. ;

Sabbagh, Marwan N. ;

Sadowsky, Carl H. ;

Reiman, P. Eric M. ;

Zehntner, Simone P. ;

Skovronsky, Daniel M. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 305 (03) :275-283

[4] Phase 3 Trial of Flutemetamol Labeled With Radioactive Fluorine 18 Imaging and Neuritic Plaque Density [J].

Curtis, Craig ;

Gamez, Jose E. ;

Singh, Upinder ;

Sadowsky, Carl H. ;

Villena, Teresa ;

Sabbagh, Marwan N. ;

Beach, Thomas G. ;

Duara, Ranjan ;

Fleisher, Adam S. ;

Frey, Kirk A. ;

Walker, Zuzana ;

Hunjan, Arvinder ;

Holmes, Clive ;

Escovar, Yavir M. ;

Vera, Carla X. ;

Agronin, Marc E. ;

Ross, Joel ;

Bozoki, Andrea ;

Akinola, Mary ;

Shi, Jiong ;

Vandenberghe, Rik ;

Lkonomovic, Milos D. ;

Sherwin, Paul F. ;

Grachev, Igor D. ;

Farrar, Gillian ;

Smith, Adrian P. L. ;

Buckley, Christopher J. ;

McLain, Richard ;

Salloway, Stephen .

JAMA NEUROLOGY, 2015, 72 (03) :287-294

[5] Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study [J].

Doraiswamy, P. M. ;

Sperling, R. A. ;

Johnson, K. ;

Reiman, E. M. ;

Wong, T. Z. ;

Sabbagh, M. N. ;

Sadowsky, C. H. ;

Fleisher, A. S. ;

Carpenter, A. ;

Joshi, A. D. ;

Lu, M. ;

Grundman, M. ;

Mintun, M. A. ;

Skovronsky, D. M. ;

Pontecorvo, M. J. .

MOLECULAR PSYCHIATRY, 2014, 19 (09) :1044-1051

[6] Added Diagnostic Value of C-11-PiB-PET in Memory Clinic Patients with Uncertain Diagnosis [J].

Frederiksen, K. S. ;

Hasselbalch, S. G. ;

Hejl, A. -M. ;

Law, I. ;

Hojgaard, L. ;

Waldemar, G. .

DEMENTIA AND GERIATRIC COGNITIVE DISORDERS EXTRA, 2012, 2 (01) :610-621

[7] Potential Impact of Amyloid Imaging on Diagnosis and Intended Management in Patients With Progressive Cognitive Decline [J].

Grundman, Michael ;

Pontecorvo, Michael J. ;

Salloway, Stephen P. ;

Doraiswamy, P. Murali ;

Fleisher, Adam S. ;

Sadowsky, Carl H. ;

Nair, Anil K. ;

Siderowf, Andrew ;

Lu, Ming ;

Arora, Anupa K. ;

Agbulos, Abigail ;

Flitter, Matthew L. ;

Krautkramer, Michael J. ;

Sarsour, Khaled ;

Skovronsky, Daniel M. ;

Mintun, Mark A. .

ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 2013, 27 (01) :4-15

[8] Recommendations from the Italian Interdisciplinary Working Group (AIMN, AIP, SINDEM) for the utilization of amyloid imaging in clinical practice [J].

Guerra, Ugo Paolo ;

Nobili, Flavio Mariano ;

Padovani, Alessandro ;

Perani, Daniela ;

Pupi, Alberto ;

Sorbi, Sandro ;

Trabucchi, Marco .

NEUROLOGICAL SCIENCES, 2015, 36 (06) :1075-1081

[9] Re-Evaluation of Clinical Dementia Diagnoses with Pittsburgh Compound B Positron Emission Tomography [J].

Gunnarsson, M. Degerman ;

Lindau, M. ;

Santillo, A. F. ;

Wall, A. ;

Engler, H. ;

Lannfelt, L. ;

Basun, H. ;

Kilander, L. .

DEMENTIA AND GERIATRIC COGNITIVE DISORDERS EXTRA, 2013, 3 (01) :472-481

[10]

Johnson KA, 2013, ALZHEIMERS DEMENT, V9, pE1, DOI [10.1016/j.jalz.2013.01.002, 10.1016/j.jalz.2013.06.001, 10.1016/j.jalz.2012.10.007]

← 1 2 3 →